This clinical trial is focused on studying a heart condition known as dilated cardiomyopathy (DCM). DCM is a disease where the heart becomes enlarged and cannot pump blood efficiently. The study is specifically looking at individuals who carry genetic variants that can cause DCM but do not yet show symptoms of the disease. The treatment being tested is a medication called candesartan, which is commonly used to treat high blood pressure and heart failure. In this trial, candesartan is being compared to a placebo to see if it can prevent changes in the heart that are associated with DCM.

The purpose of the study is to determine if early treatment with candesartan can prevent a significant decline in the heart’s ability to pump blood, known as left ventricular ejection fraction (LVEF), or an increase in the size of the heart’s main pumping chamber, known as left ventricular end-diastolic volume (LVEDV). Participants in the study will be randomly assigned to receive either candesartan or a placebo. The study will monitor changes in LVEF and LVEDV over time using magnetic resonance imaging (MRI), a type of scan that provides detailed images of the heart.

The trial will last for several years, during which participants will have regular check-ups and MRI scans to track any changes in their heart function. The study aims to see if candesartan can help prevent the progression of DCM in people who are at risk but do not yet have symptoms. This research could provide valuable insights into the early treatment of DCM and potentially improve outcomes for those with a genetic predisposition to the disease.